Achieving commercial success for an IVD product or an LDT assay is becoming progressively more difficult in the current healthcare environment. The combination of tightening budgets and the launch of a large number of expensive molecular tests creates complications for payers to respond in traditional ways. Cambridge Healthtech Institute’s 2nd Annual Dx Reimbursement Outlook symposium will provide its participants with a unique opportunity to discuss winning strategies with government and private payers as well as with their peers who are working on similar tasks.
https://www.triconference.com/Dx-Reimbursement-Outlook